Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Abraham, Avigdor"'
Autor:
Ohad Benjamini, Shalev Fried, Roni Shouval, Jessica R. Flynn, Ofrat Beyar-Katz, Lori A Leslie, Tsilla Zucherman, Ronit Yerushalmi, Noga Shem-Tov, Maria Lia Palomba, Ivetta Danylesko, Inbal Sdayoor, Hila Malka, Orit Itzhaki, Hyung Suh, Sean M. Devlin, Ronit Marcus, Parastoo B Dahi, Elad Jacoby, Gunjan L Shah, Craig S Sauter, Andrew Ip, Miguel-Angel Perales, Arnon Nagler, Avichai Shimoni, Michael Scordo, Abraham Avigdor
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and effica
Externí odkaz:
https://doaj.org/article/446c107a98b1415f962e7e3be018edfa
Autor:
Junichiro Yuda, Christine Will, Darren C. Phillips, Linu Abraham, Cory Alvey, Abraham Avigdor, Wayne Buck, Lauren Besenhofer, Erwin Boghaert, Dong Cheng, Dan Cojocari, Kelly Doyle, T. Matthew Hansen, Kevin Huang, Eric F. Johnson, Andrew S. Judd, Russell A. Judge, John C. Kalvass, Aaron Kunzer, Lloyd T. Lam, Rachel Li, Ruth L. Martin, Anthony Mastracchio, Mike Mitten, Adam Petrich, Jin Wang, James E. Ward, Haichao Zhang, Xilu Wang, Johannes E. Wolff, Katherine M. Bell-McGuinn, Andrew J. Souers
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Abstract Background MCL-1 is a prosurvival B-cell lymphoma 2 family protein that plays a critical role in tumor maintenance and survival and can act as a resistance factor to multiple anticancer therapies. Herein, we describe the generation and chara
Externí odkaz:
https://doaj.org/article/a09a2953c50e4da8ad9915dfa149ffac
Autor:
Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102130- (2023)
Summary: Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) asse
Externí odkaz:
https://doaj.org/article/c66821b07c654aec8c095879560486da
Autor:
John Timmerman, David Lavie, Nathalie Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Publikováno v:
HemaSphere, Vol 7, p e5990067 (2023)
Externí odkaz:
https://doaj.org/article/22031be9c69f424280efb74b4ea89e20
Autor:
Nathalie Johnson, David Lavie, Peter Borchmann, Gareth Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Publikováno v:
HemaSphere, Vol 7, p e0274602 (2023)
Externí odkaz:
https://doaj.org/article/a8737852cae34698a0c1cb539063a54a
Autor:
Mika Geva, Shalev Fried, Orit Itzhaki, Noga Shem-Tov, Ivetta Danylesko, Ronit Yerushalmi, Ronit Marcus, Inbal Sdayoor, Ronnie Shapira-Frommer, Meirav Kedmi, Roni Shouval, Arnon Nagler, Avichai Shimoni, Abraham Avigdor
Publikováno v:
HemaSphere, Vol 7, p e62933fb (2023)
Externí odkaz:
https://doaj.org/article/e0575545a9cb4703885b16f12c06ef66
Autor:
Gal Sharvit, Daniel Schwartz, Gabriel Heering, Alexander Shulman, Abraham Avigdor, Galia Rahav, Amos Toren, Arnon Nagler, Jonathan Canaani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract The clinical yield and benefit of performing bone marrow cultures for various clinical indications has been challenged and their clinical necessity remains debatable. We sought to assess the clinical yield and benefit of performing routine b
Externí odkaz:
https://doaj.org/article/a69132e642354dafa5896661b6c39ff8
Autor:
Abraham Avigdor, Fabrizio Trinchese, Francois Gavini, Nawal Bent‐Ennakhil, Mehul Dalal, Athanasios Zomas, Sharmeen Gettner Broun, Guido Gini
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 415-425 (2022)
Abstract Classical Hodgkin lymphoma (cHL) is curable in 90% of cases, but advanced stage patients who do not respond well to first‐line (1L) therapy have poorer outcomes. This retrospective study examines patient characteristics, treatment patterns
Externí odkaz:
https://doaj.org/article/d8aaca1bd51742e6a3075eac414b7e19
Autor:
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0284925 (2023)
Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody respon
Externí odkaz:
https://doaj.org/article/d9adb0c1b39542be959dd8b59e562969
Autor:
Yaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Jonathan Canaani, Abraham Avigdor, Ronit Yerushalmi, Arnon Nagler, Avichai Shimoni
Publikováno v:
Haematologica, Vol 108, Iss 7 (2022)
Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after a first transplant (HSCT1). However, patients allocated to HSCT2 m
Externí odkaz:
https://doaj.org/article/2c026f95013347f9a2f10827bb605435